Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Seattle Genetics initiates phase I trial of SGN-10 combination therapy

Sep. 21, 2000

Maxamine scheduled for December advisory panel review

Sep. 20, 2000

Cel-Sci receives grant for cervical cancer study with Multikine

Sep. 20, 2000

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

Sep. 15, 2000

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Sep. 15, 2000

NCI sponsors additional phase II studies of Prostvac VF vaccine

Sep. 13, 2000

StressGen commences phase II trial of HspE7 for treatment of cervical cancer

Sep. 12, 2000

Maxamine granted priority FDA review for melanoma

Sep. 8, 2000

Herceptin approved in E.U. for treatment of HER2-positive metastatic breast cancer

Aug. 30, 2000

Cancer vaccine shows potential for decreasing risk of relapse and death

Aug. 30, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...